"I see a neurologist every six months, have access to disease modifyingtreatment drugs and easy access to my MS nurse, who I can see in 15 minutes if I need to, " he said.
That, he says, is exactly what would be needed for the drug to be approved by the Food and Drug Administration as a disease-modifying agent, not just a treatment of symptoms.